Gareth J Morrison1, Amir Goldkorn2. 1. Division of Medical Oncology, Department of Medicine, Keck School of Medicine and Translational and Clinical Science Program, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. 2. Division of Medical Oncology, Department of Medicine, Keck School of Medicine and Translational and Clinical Science Program, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. agoldkor@med.usc.edu.
Abstract
PURPOSE OF REVIEW: Metastatic prostate cancer is a lethal and highly heterogeneous malignancy, associated with a broad spectrum of potentially actionable molecular alterations. In the past decade, disease profiling has expanded to include not only traditional tumor tissue, but also liquid biopsies of cells and genetic material circulating in the blood. These liquid biopsies offer a minimally invasive, repeatable source of tumor material for longitudinal disease profiling but also raise new technical and biological challenges. Here we will summarize recent advances in liquid biopsy strategies and the role they have played in biomarker development and disease management. RECENT FINDINGS: Technologies for analysis of circulating tumor cells (CTCs) continue to evolve rapidly, and the latest high content scanning platforms have underscored the phenotypic heterogeneity of CTC populations. Among liquid biopsies, CTC enumeration remains the most extensively validated prognostic marker to date, but other clinically relevant phenotypes like androgen receptor (AR) localization or presence of AR-V7 splice variant are important new predictors of therapy response. Serial genomic profiling of CTCs or circulating tumor DNA (ctDNA) is helping to define primary and acquired resistance mechanisms and helping to guide patient selection for targeted therapies such as poly(adenosine diphosphate [ADP] ribose) polymerase (PARP) inhibition. The era of liquid biopsy-based biomarkers has arrived, driven by powerful new enrichment and analysis techniques. As new blood-based markers are identified, their biological significance as disease drivers must be elucidated to advance new therapeutic strategies, and their clinical impact must be translated through assay standardization, followed by analytical and clinical validation. These efforts, already ongoing on multiple fronts, constitute the critical steps toward more effective precision management of advanced prostate cancer.
PURPOSE OF REVIEW: Metastatic prostate cancer is a lethal and highly heterogeneous malignancy, associated with a broad spectrum of potentially actionable molecular alterations. In the past decade, disease profiling has expanded to include not only traditional tumor tissue, but also liquid biopsies of cells and genetic material circulating in the blood. These liquid biopsies offer a minimally invasive, repeatable source of tumor material for longitudinal disease profiling but also raise new technical and biological challenges. Here we will summarize recent advances in liquid biopsy strategies and the role they have played in biomarker development and disease management. RECENT FINDINGS: Technologies for analysis of circulating tumor cells (CTCs) continue to evolve rapidly, and the latest high content scanning platforms have underscored the phenotypic heterogeneity of CTC populations. Among liquid biopsies, CTC enumeration remains the most extensively validated prognostic marker to date, but other clinically relevant phenotypes like androgen receptor (AR) localization or presence of AR-V7 splice variant are important new predictors of therapy response. Serial genomic profiling of CTCs or circulating tumor DNA (ctDNA) is helping to define primary and acquired resistance mechanisms and helping to guide patient selection for targeted therapies such as poly(adenosine diphosphate [ADP] ribose) polymerase (PARP) inhibition. The era of liquid biopsy-based biomarkers has arrived, driven by powerful new enrichment and analysis techniques. As new blood-based markers are identified, their biological significance as disease drivers must be elucidated to advance new therapeutic strategies, and their clinical impact must be translated through assay standardization, followed by analytical and clinical validation. These efforts, already ongoing on multiple fronts, constitute the critical steps toward more effective precision management of advanced prostate cancer.
Authors: Jamie M Sperger; Lindsay N Strotman; Allison Welsh; Benjamin P Casavant; Zachery Chalmers; Sacha Horn; Erika Heninger; Stephanie M Thiede; Jacob Tokar; Benjamin K Gibbs; David J Guckenberger; Lakeesha Carmichael; Scott M Dehm; Philip J Stephens; David J Beebe; Scott M Berry; Joshua M Lang Journal: Clin Cancer Res Date: 2016-07-11 Impact factor: 12.531
Authors: Emmanuel S Antonarakis; Changxue Lu; Brandon Luber; Hao Wang; Yan Chen; Yezi Zhu; John L Silberstein; Maritza N Taylor; Benjamin L Maughan; Samuel R Denmeade; Kenneth J Pienta; Channing J Paller; Michael A Carducci; Mario A Eisenberger; Jun Luo Journal: J Clin Oncol Date: 2017-04-06 Impact factor: 44.544
Authors: Jens G Lohr; Viktor A Adalsteinsson; Kristian Cibulskis; Atish D Choudhury; Mara Rosenberg; Peter Cruz-Gordillo; Joshua M Francis; Cheng-Zhong Zhang; Alex K Shalek; Rahul Satija; John J Trombetta; Diana Lu; Naren Tallapragada; Narmin Tahirova; Sora Kim; Brendan Blumenstiel; Carrie Sougnez; Alarice Lowe; Bang Wong; Daniel Auclair; Eliezer M Van Allen; Mari Nakabayashi; Rosina T Lis; Gwo-Shu M Lee; Tiantian Li; Matthew S Chabot; Amy Ly; Mary-Ellen Taplin; Thomas E Clancy; Massimo Loda; Aviv Regev; Matthew Meyerson; William C Hahn; Philip W Kantoff; Todd R Golub; Gad Getz; Jesse S Boehm; J Christopher Love Journal: Nat Biotechnol Date: 2014-04-20 Impact factor: 54.908
Authors: Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: David T Miyamoto; Yu Zheng; Ben S Wittner; Richard J Lee; Huili Zhu; Katherine T Broderick; Rushil Desai; Douglas B Fox; Brian W Brannigan; Julie Trautwein; Kshitij S Arora; Niyati Desai; Douglas M Dahl; Lecia V Sequist; Matthew R Smith; Ravi Kapur; Chin-Lee Wu; Toshi Shioda; Sridhar Ramaswamy; David T Ting; Mehmet Toner; Shyamala Maheswaran; Daniel A Haber Journal: Science Date: 2015-09-18 Impact factor: 47.728
Authors: Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson Journal: N Engl J Med Date: 2016-07-06 Impact factor: 91.245
Authors: Emmanuelle Hodara; Gareth Morrison; Alexander Cunha; Daniel Zainfeld; Tong Xu; Yucheng Xu; Paul W Dempsey; Paul C Pagano; Farideh Bischoff; Aditi Khurana; Samuel Koo; Marc Ting; Philip D Cotter; Mathew W Moore; Shelly Gunn; Joshua Usher; Shahrooz Rabizadeh; Peter Danenberg; Kathleen Danenberg; John Carpten; Tanya Dorff; David Quinn; Amir Goldkorn Journal: JCI Insight Date: 2019-03-07
Authors: Amir Goldkorn; Catherine Tangen; Melissa Plets; Gareth J Morrison; Alexander Cunha; Tong Xu; Jacek K Pinski; Sue A Ingles; Timothy Triche; Andrea L Harzstark; Manish Kohli; Gary R MacVicar; Daniel A Vaena; Anthony W Crispino; David J McConkey; Primo N Lara; Maha H A Hussain; David I Quinn; Nicholas J Vogelzang; Ian Murchie Thompson; Neeraj Agarwal Journal: Clin Cancer Res Date: 2021-01-26 Impact factor: 13.801
Authors: Michelle M Kouspou; Jenna E Fong; Nadine Brew; Sarah T F Hsiao; Seanna L Davidson; Peter L Choyke; Tony Crispino; Suneil Jain; Guido W Jenster; Beatrice S Knudsen; Jeremy L Millar; Nicole Mittmann; Charles J Ryan; Bertrand Tombal; Mark Buzza Journal: Nat Rev Urol Date: 2020-07-22 Impact factor: 14.432